Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease : an overview of systematic reviews by Studziński, Krzysztof et al.
RESEARCH ARTICLE Open Access
Effect of using cardiovascular risk scoring in
routine risk assessment in primary
prevention of cardiovascular disease: an
overview of systematic reviews
Krzysztof Studziński1,3, Tomasz Tomasik1,3* , Janusz Krzysztoń1,3, Jacek Jóźwiak2,3 and Adam Windak1,3
Abstract
Background: Our objectives were to critically appraise and summarise the current evidence for the effectiveness of
using cardiovascular disease (CVD) risk scoring (total risk assessment - TRA) in routine risk assessment in primary
prevention of CVD compared with standard care with regards to patients outcomes, clinical risk factor levels,
medication prescribing, and adverse effects.
Methods: We carried out an overview of existing systematic reviews (SRs). Presentation of the results aligned
guidelines from the PRISMA statement. The data is presented as a narrative synthesis. We searched MEDLINE
(Ovid), EMBASE, CENTRAL and SCOPUS databases from January 1990 to March 2017, reviewed the reference
lists of all included SRs and searched for ongoing SRs in PROSPERO database. We encompassed SRs and meta-analyses
which took into account RCTs, quasi-RCTs, and observational studies investigating the effect of using CVD risk scoring.
Only studies performed in a primary care setting, with adult participants free of clinical CVD were eligible. Intervention
was CVD risk assessment with use of the total CVD risk scoring compared with standard care with no use of TRA .
Results: We identified 2157 records, we then recognised and analysed 10 relevant SRs. One SR reported statistically
insignificant reduction of CVD death, when using TRA, the second SR presented meta-analysis which reported
no effect on fatal and non-fatal CV events compared with conventional care (5.4% vs 5.3%; RR 1.01, 95% CI 0.95 to
1.08; I2 = 25%). Three SRs have shown that using TRA causes no adverse events. The impact of TRA on global CVD risk
as well as individual risk factors is ambiguous, but a tendency towards slight reduction of blood pressure, total
cholesterol and smoking levels, especially in high risk patient groups was observed. TRA had no influence on
lifestyle behaviour.
Conclusions: There is limited evidence, of low overall quality, suggesting a possible lack of effectiveness of
TRA in reducing CVD events and mortality, as well as a clinically insignificant influence on individual risk factor
levels. Using TRA does not cause harm to patients.
Trial registration: Systematic review protocol was registered with the International PROSPERO database - registration
number CRD42016046898.
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Introduction
Cardiovascular disease (CVD) is presently the leading
cause of mortality, morbidity and disability worldwide
[1, 2]. Well-established, modifiable CVD risk factors in-
clude: elevated blood pressure, hypercholesterolaemia,
diabetes, lack of physical activity, obesity, inappropriate
diet, and smoking [3, 4].
In 1961, Kannel et al. [5] used the term “factors of risk”
for the first time and proved that hypertension, hyperchol-
esterolaemia and other risk factors precede the develop-
ment of coronary heart disease [CHD] in humans.
Understanding CVD risk factors makes prevention
possible. Risk factor modification can reduce the number
of premature deaths as well as the number of other clin-
ical events, both in people without established CVD (pri-
mary prevention) and people with confirmed CVD
(secondary prevention) [6].
Following Kannel’s work, a new concept of the abso-
lute/global/total CVD risk has become widely adopted.
By definition, absolute CVD risk is the actual risk of de-
veloping the disease within a defined population in a de-
fined period of time (typically 5 or 10 years) [7]. The
absolute CVD risk is calculated by using a combination
of major risk factors. Risk score algorithms incorporating
multiple risk factors are used to calculate absolute risk
for an individual patient [8].
The number of risk scores developed in European
countries, USA and other parts of the world have grown
rapidly. In 2016, Damen et al. [9] identified 363 prognos-
tic models or risk-scoring methods with potential use in
targeting primary prevention of CVD. Contemporarily,
the most well-known and widely used are: Systematic
COronary Risk Evaluation (SCORE) algorithm [10],
QRISK2 [11], the World Health Organization (WHO)
risk score, and the American College of Cardiology/
American Heart Association (ACC/AHA) 2013 Pooled
Cohort risk equations [12].
Presently, major clinical practice guidelines (CCS [13],
ESC/ESH [6], ACC/AHA [14], JBS3 [15]) recommend
assessing risk of CVD using the absolute/global/total
CVD risk scores. It is stated that the use of CVD risk
scores increases the accuracy of prediction of CVD events
and guides management decisions in primary prevention.
The effectiveness of using absolute/global/total CVD
risk scores called also total risk assessment (TRA) has
been assessed by numerous randomised control trials
(RCTs), published over the last two decades. The re-
search community also tried to summarise existing evi-
dence in this field, which resulted in the publication of a
few systematic reviews (SRs) [16–19]. However, despite
numerous studies, there are still some unsolved issues.
One of them is whether using TRA is clinically effective
when important outcomes for patients are taken into ac-
count (e.g. mortality, CV events). Even when TRA
appropriately predicts CV events, it does not mean that
beneficial clinical effects will occur. Furthermore, there
is a lack of data about the potential adverse effects of
TRA. The absence of information does not mean that
this procedure is completely safe.
Summing up, the effectiveness of using TRA in
clinical practice is still poorly understood. Although it
may be beneficial and improve health (e.g. identifying
high-risk individuals who will most likely benefit from
risk factor management), it may also be harmful (e.g.
undertreatment of the youth, overtreatment of the
elderly) and lead to misuse of resources (e.g. time
and cost of laboratory tests).
Objectives
This study has the following objectives: (1) to critically
apprise and summarise the best current evidence for the
effectiveness of using TRA in routine risk assessment in
primary prevention of CVD compared with standard
care; (2) to assess whether use of a particular risk score
followed by structured or unstructured intervention is
more effective than any other risk score in improving
patient outcomes and (3) to discuss how our findings
can be used to guide clinicians and policymakers, and
provide a guideline for future authors.
Methods
Protocol and registration
Our systematic review protocol was registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) on 01 September 2016 (registration num-
ber CRD42016046898). The full version of the protocol
was later published in the BMJ Open [20]. Any devia-
tions from this plan, which were minor, are described in
Additional file 1.
Eligibility criteria
Studies were selected according to the prespecified cri-
teria defined below. Those criteria were also mentioned
in detail in the full version of the protocol of our study
published in the BMJ Open [20].
Study design
We performed an overview of SRs and meta-analyses
which took into account RCTs, quasi-RCTs, and obser-
vational studies investigating the effect of using CVD
risk scoring in routine risk assessment in primary pre-
vention of CVD.
Participants
Only studies with adult participants (19 years of age and
over) and free of clinical CVD, were eligible. Studied pa-
tients may have had different CVD risk factors or other
diseases including diabetes and chronic kidney disease.
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Intervention
CVD risk assessment with use of total risk assessment
(TRA), performed by physicians or other healthcare
professionals.
Comparator
Standard care with no use of the global CVD risk scor-
ing provided by a physician or healthcare professional.
Outcomes
Primary outcomes (1) CVD death, (2) Fatal and non-
fatal cardiovascular events, (3) Adverse events (any phys-
ical, psychological or social events).
Secondary outcomes (1) All-cause mortality, (2)
Change in predicted global CVD risk, (3) Change in
patient CVD risk factors - change in blood pressure,
cholesterol level, smoking, exercise, diet, alcohol con-
sumption and obesity, (4) Prescription of risk-reducing
drugs according to prevailing guidelines (aspirin, anti-
hypertensives, lipid-lowering drugs), (5) Pharmaco-
therapy without or against current clinical guideline
recommendations.
Adverse events mentioned as primary outcomes could
be as follows: (1) physical – e.g. hypertension or dyslipi-
daemia complications in young patients who were ex-
cluded from pharmacotherapy due to low CVD risk score;
(2) psychological – e.g. anxiety, depression, stress caused
by diagnosis and being labelled as “chronically ill”; (3) so-
cial – e.g. cost and additional time spent on unnecessary
consultations, role changing in family or society.
Setting
Only studies performed in an outpatient setting were eli-
gible since TRA guides management decision in primary
prevention in patients without known CVD.
Search strategy
We searched MEDLINE (Ovid), EMBASE, CENTRAL
(Cochrane Central Register of Controlled Trials) and
SCOPUS databases from January 1990 to March 2017.
All databases from 1990 onwards were scanned because
only a very small number of systematic reviews had been
conducted before that time [21, 22]. The search was lim-
ited to English language literature. It was supplemented
by a search for unpublished, ongoing, or recently com-
pleted systematic reviews in PROSPERO database. In
addition, we reviewed the reference lists of all included
systematic reviews. Our detailed search strategy for
MEDLINE is presented in Additional file 2.
Data management
All identified records were uploaded or manually en-
tered into Mendeley v1.17.6 (Elsevier). After duplicate
removal, titles and abstracts from the searches were in-
dependently screened by two authors. Full-text articles
were retrieved for all potentially includable SRs. Any dis-
agreements were resolved through discussion. In case of
lack of consensus, a third author was arbitrated.
The methodology for data extraction and analysis was
based on guidance from Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment [23] and the Cochrane Handbook of Systematic
Reviews of Interventions [24]. The PRISMA checklist is
presented in an Additional file 3. Two authors independ-
ently extracted outcome data from each included SR
using a predefined data extraction form. Disagreements
during the data extraction process were resolved
through discussion or arbitrarily by a third author.
We have extracted the following information: (1) ad-
ministrative and bibliographic data; (2) the characteris-
tics of each review; (3) methodological details and
results of meta-bias assessments (if conducted); (4) re-
ported limitations of each review; (5) results and conclu-
sions of the review.
If meta-analysis was presented in one of the included
SRs, we extracted both its results and all relevant meth-
odological aspects (e.g. types and unity of data, effect
measured, heterogeneity, sensitivity analysis). As we spe-
cified in our overview protocol [20], we did not conduct
a meta-analysis of meta-analyses, mainly because of the
risk of introducing bias. According to Smith et al. [25]
and Pieper et al. [26], such undesired bias can be easily
incorporated (due to giving excessive statistical power to
primary studies included in more than one systematic
review) when performing meta-analysis in review of sys-
tematic reviews. Additionally, the same authors highlight
that there is no well-established quantification method
in this field.
Additionally, we looked at the following information:
(1) outcomes reported in a particular SR which were
recognised by the authors as evidence of the effective-
ness of TRA, (2) reported effect of TRA in different
populations, (3) reported effect of different TRA in the
same population.
Risk of bias in included systematic reviews
Two reviewers independently appraised risk of bias of
the included systematic reviews using a validated assess-
ment of multiple systematic reviews (AMSTAR) check-
list, which is the most commonly employed method to
assess the quality of systematic reviews included in over-
views [27]. We scored each systematic review with a
maximum of 11 points. Disagreements were resolved
through discussion or arbitrarily by a third author. Each
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systematic review was assigned to one of three quality
levels (0–3 points - low quality, 4–7 points - medium
quality and 8–11 points - high quality) [28, 29].
Risk of bias across systematic reviews
To assess selective outcome reporting within systematic
reviews, we compared those which were planned to be
assessed in the systematic review protocols (or, if un-
available, in the methods section of the published report
of SR) and other outcomes reported in the results sec-
tion of the published report of SR. To minimise publica-
tion bias, we identified all relevant ongoing SRs by
searching the PROSPERO database. To assess the degree
of overlap in the inclusion of primary studies between
systematic reviews, the citation matrix was generated by
one reviewer and checked by a second for accuracy
(Additional file 4). The degree of overlap was calculated
with use of the corrected cover area (CCA) in our cit-
ation matrix by an experienced statistician [26].
Results
After duplicates were removed, the electronic search iden-
tified 2045 papers. One hundred twelve records from
other sources were added (104 records of ongoing or re-
cently completed SRs from PROSPERO database, 7 papers
found in the reference sections of known SRs and one re-
ceived due to contact with the authors). 2157 records were
independently screened by two authors. Fifteen full-text
articles were screened for eligibility, of which 4 were not
related to the effectiveness of TRA [30–33], 1 was not SR
[34], and the remaining 10 SRs included 66 unique pri-
mary studies and were included (see Additional file 4).
Flow diagram is presented at Fig. 1.
Summary of included systematic reviews
Characteristics of included systematic reviews are pre-
sented in Table 1.
The review performed by Brindle et al. [16] focused
both on the accuracy and impact of CVD risk assess-
ment in primary prevention. The authors performed
comprehensive searches across 6 databases. The majority
of included studies focused on CVD risk assessment ac-
curacy. The authors identified 4 RCTs assessing effect-
iveness of using CVD risk score. As the quality of
evidence was unclear, the authors concluded that it was
insufficient to support the claim that CVD risk assess-
ment performed by clinicians improves health outcomes.
Sheridan and Crespo [17] focused on the benefits and
harms of physicians’ knowledge of CVD risk scoring.
The authors searched one database (MEDLINE) and
identified 11 primary studies. They concluded that “physi-
cians’ knowledge of global CHD risk scores may translate
into modestly increased prescribing of cardiovascular
drugs and modest short-term reductions in CHD risk fac-
tors without clinical harm”.
The SR by Sheridan et al. [18] aimed at evaluating the
effectiveness of presenting CVD risk information to pa-
tients as a primary intervention versus part of a multi-
part intervention. The researchers studied 4 databases
and considered studies of any quantitative experimental
design. They identified 18 primary studies of good or fair
quality. Results suggested that providing CVD risk infor-
mation to the patients may “improve accuracy of risk
perception and may increase intent to initiate CHD pre-
vention”. However, the effect on more long-term out-
comes was not clear.
Waldron et al. [35] tried to assess the effectiveness of
using different methods of communicating CVD risk
and the impact of these methods on patient-related out-
comes. The authors performed comprehensive searches
across 6 databases. However, only 4 out of the 15 quanti-
tative studies included assessed individuals’ actual risk.
The majority of these studies were analogue studies
using hypothetical risk profiles. The authors concluded
that there were not many well-designed studies focusing
on CVD risk communication.
In their review, Van Dieren et al. [36] aimed to identify
all papers presenting CVD prediction models developed
in either diabetic or general patient populations that in-
cluded diabetes as a predictor. The review also identified
studies examining the impact of applying a prediction
model in clinical practice. They found 3 studies of this
type, all of which utilised the Framingham prediction
model. Results suggested that it is still unknown whether
the use of these models indeed changes the treatment of
patients with diabetes mellitus or whether it reduces the
number of cardiovascular complications.
Willis et al. [19] aimed to evaluate the effectiveness of
using validated CVD risk scores to identify individuals at
highest risk followed by intervention as a means of redu-
cing CVD risk or mortality. They included 5 full texts in
their review. Two trials reported a reduction in CVD
mortality. However one of them showed a lack of statis-
tical significance, and in the second, the p value was not
provided. The authors concluded that “evidence suggests
that lifestyle interventions aimed at the primary preven-
tion of CVD that use validated risk scores to recruit high
risk individuals show potential for lowering CVD mor-
tality and the incidence of cardiovascular events”.
Usher-Smith et al. [37] searched for interventional
studies which involved providing a CVD risk assessment
to patients or their providers. Final analysis was based
on 17 primary studies. Results suggested that providing
patients with risk information improves the accuracy of
perceived risk without increasing anxiety or decreasing
quality of life. Additionally, it leads to a small reduction
in cholesterol and blood pressure despite a lack of
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evidence that this reduction is due to lifestyle changes.
Moreover, providing risk information increases the fre-
quency of prescribing lipid-lowering and blood pressure
medications.
Tomasik et al. [38] focused only on the effect of
using the specifically European total CVD risk estima-
tion from SCORE. A comprehensive search did not
reveal any study that compared important clinical
outcomes (death, major events, adverse events) be-
tween groups that used the SCORE model and those
who did not. The authors concluded that a demon-
stration of the benefits of using SCORE is still lacking
and that current use of this tool as a preventive strat-
egy is not supported by evidence.
The Cochrane review by Karmali et al. [39] focused on
the effect of physicians, other healthcare professionals or
the health system providing a multivariable CVD risk
score. They identified 41 RCTs having multiple limitations,
substantial heterogeneity and high or unclear risk of
bias. Results suggested that the use of CVD risk
scores has little or no effect on CVD events com-
pared with standard care, though to a small extent it
may reduce risk factor level (systolic BP, total choles-
terol), multivariable CVD risk, or adverse events. It
may also increase the use of antihypertensive and
lipid-lowering pharmacotherapy.
The Collins et al. [40] review of systematic reviews
summarises results from 6 SRs on the impact of global
CVD risk assessment in primary prevention. No identi-
fied review reported results such as mortality or CVD
morbidity. The authors also undertook ad hoc meta-ana-
lysis and extracted data from 16 primary studies of the
identified publications. They showed small and possibly
clinically insignificant reductions in systolic BP, choles-
terol level and smoking cessation. The quality of evi-
dence was low or very low (GRADE score).
Fig. 1 Flow diagram
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The general conclusions about the included SRs is that
there is currently little evidence that providing TRA has
a significant impact on important patient outcomes.
Biases in included systematic reviews and across systematic
reviews
AMSTAR ratings ranged from 3/11 to 10/11 (mean 6.1/
11); no SRs were excluded based on quality (see Fig. 2).
Ten eligible SRs included 66 unique primary studies.
Thirty five publications were encompassed in only one
SR and 31 in more than one. The measure of overlap by
corrected covered area (CCA) was 9%, indicating a mod-
erate overlap [26]. Details of calculations and the list of
primary studies are presented in Additional file 4.
In the majority of the SRs, the authors presented the
same outcomes in the results sections that they had
planned to assess in their initial protocols or in the
methodology section of published reports. Collins et al.
[40] deviated from their registered protocol, which they
reported in Additional file 1, published online. They had
originally planned to explore many different outcomes,
but instead focused on what they deemed to be the most
important ones: CVD-related morbidity and mortality as
primary outcomes and systolic blood pressure, cholesterol,
and smoking as secondary outcomes. Willis et al. [19]
additionally reported cardiovascular disease risk factors
which were not in the original scope of their work.
Effects of interventions
Primary outcomes
CVD death and fatal and non-fatal CVD event The
SR by Willis et al. [19] included two original studies
reporting changes in coronary [CHD] death [41, 42]. In
one of the studies [41] the authors reported a lowering
of CVD deaths of 4.7% without indicating if the differ-
ence is statistically significant. In another study [42], the
reduction of CHD deaths of 7.4% was not statistically
significant (p > 0.05). These two original studies were not
mentioned or included in any other SR. Both studies
were published in the 1980’s, when strategies for CVD
risk reduction were far more limited. Additionally, these
trials were really designed with the intent of examining
the effectiveness of a high intensity intervention geared
at risk factor modification, rather than the use of risk
scores. Both studies only included men.
Karmali et al. [39] presented a meta-analysis of three
studies on the effect of providing TRA on fatal and
Fig. 2 Assessment of the methodological quality of the included systematic reviews (AMSTAR). Legend: White = Yes; Black = No; Grey = can’t
answer/unclear; N/A = not applicable
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non-fatal CV events. It reported no effect compared
with conventional care (5.4% vs 5.3%; risk ratio [RR]
1.01, 95% confidence interval [CI] 0.95 to 1.08; I2 = 25%).
Included in meta-analysis studies had low quality with
high or unclear risk of bias. Furthermore, 2 of these
studies were likely underpowered for assessment of
CVD events due to limited recruitments of participants
over the age of 50 years and low rates of CVD events.
The third study included a cohort of patients with HIV,
which is not generalizable.
Adverse events Authors of three SRs [17, 37, 39] were
looking for possible adverse events of CVD risk assess-
ment. These SRs showed no difference in the presence
of psychological symptoms in groups with or without
TRA. Usher-Smith et al. [37] also showed a small im-
provement in psychological well-being (measured with
GHQ-28 scores) and level of anxiety in high CVD risk
patients after TRA.
One SR [39] reported low-quality evidence suggesting
that providing TRA may reduce the presence of adverse
physical events (1.9% vs 2.7%; RR 0.72, 95% CI 0.49 to
1.04; I2 = 0%).
The detailed results of all primary outcomes are pre-
sented in Table 2.
Secondary outcomes
All-cause mortality None of the included SRs reported
changes in all-cause mortality.
Change in predicted global CVD risk and CVD risk
factors. Four SRs reported reduction of predicted global
CVD risk after providing TRA [17, 19, 37, 39]. One SR
[18] showed mixed results and another SR [16] showed
no difference. Seven SRs showed a tendency towards a
small reduction of BP [16–19, 37, 39, 40]. The authors
of eight SRs assessed possible changes in cholesterol
level. They showed mixed results with the tendency to-
wards reduction of TC [16–19, 35, 37, 39, 40]. There was
no change in reported obesity level [17, 37], diet used [16,
37, 39] or alcohol consumption [37], but a slight reduction
in smoking was noted [18, 19, 37, 39, 40].
Details are presented in Table 3.
Prescription of risk-reducing drugs according and
against guidelines Five SRs [16, 17, 36, 37, 39] reported
the impact of TRA on prescription of risk-reducing
drugs. The results were mixed, but in all they suggest
that TRA use may increase or have no effect on pre-
scription of aspirin, anti-hypertensive and lipid-lowering
drugs in all CVD risk groups. They also suggest that pre-
scription of anti-hypertensive and lipid-lowering drugs
in high CVD risk groups is increased.
One SR [39] reported the effect of providing TRA to
patients on prescription of drugs against guidelines.
Detailed data is presented in Table 4.
We were unable to find any studies comparing the use
of different risk models followed by structured or un-
structured intervention showing that one is more effect-
ive than another.
The majority of SRs (n = 8) recommend that further
effectiveness studies are needed. Five SRs propose high
quality RCTs. One of these SRs proposes a cluster RCT
with CVD mortality and morbidity data as primary out-
comes. Two SRs propose trials with surrogate outcomes
(CVD risk factor levels), which may be more feasible
due to a smaller population and less time needed.
Discussion
Main findings
We have identified and analysed 10 SRs which were
published between 2006 and 2017. Two of them re-
ported the impact of performing TRA on mortality, fatal
and non-fatal CV events. One medium quality SR [19]
revealed 2 primary studies reporting reduction of CVD
death, but it was statistically insignificant or significance
was not reported in the original study. Other high qual-
ity SR [39] presented meta-analysis of 3 primary studies
which showed no significant differences concerning fatal
and non-fatal CV events. Primary studies included in
both SRs had important limitations.
Three SRs [17, 37, 39] have analysed the impact of
performing TRA on adverse events. It was shown that
using TRA causes no difference in presence of psycho-
logical or physical events.
The impact of TRA on global CVD risk and individual
risk factors is ambiguous, but a tendency towards slight
reduction of BP, TC and smoking levels, especially in
high risk patients group, was observed. TRA had no in-
fluence on lifestyle behaviour.
Strengths and limitations
To the best of our knowledge this is the largest overview
of SRs in this area. We included 10 SRs while a previous
overview published in March 2017 covered six [40]. Our
overview of SRs was conducted strictly according to the
protocol, which was registered with the PROSPERO
database, and later published in the BMJ Open [20].
Other strengths are a robust search strategy prepared by
an experienced librarian, and broad inclusion criteria.
There are some obvious limitations to our overview of
SRs. We did not review the quality of each study in-
cluded in the SRs, nor perform an independent analysis
of data (which is standard procedure when performing
overview of SRs). The electronic search strategy was lim-
ited to 4 main international bibliographic databases and
English language literature only. Grey literature for
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unpublished papers was not studied, however a search
for ongoing or recently completed systematic reviews in
the PROSPERO database was performed. In addition,
we also manually reviewed the reference lists of all
included SRs.
Comparison with other studies and opinions
Collins et al. [40] completed searches for their overview
of SR in October 2016. They did not find SRs concern-
ing their primary outcomes (CVD mortality and morbid-
ity and all-cause mortality). The conclusions of that
overview differ from ours and the authors stated that
“there is currently no evidence that the prospective use
of global cardiovascular risk assessment translates to re-
ductions in CVD morbidity or mortality”. We hold the
view that there is a limited evidence for the lack of these
reductions.
Results of our overview of SRs can be also compared
with evidence constituting the basis for recommenda-
tions within national and international guidelines. Major
clinical practice guidelines (CCS [13], ESC/ESH [6],
ACC/AHA [14], JBS3 [15], NICE [43]) recommend
assessing risk of CVD using TRA. It is stated that use of
these risk scores increases the accuracy of prediction of
CVD events and guides management decisions in pri-
mary prevention. Some guidelines indicate that there is
no proof for the effectiveness of TRA [6]. Our research
has shown the contrary - there is a limited evidence, of
low overall quality, for a lack of effectiveness of TRA on
CVD events.
There are publications indicating, similar to our study,
that some primary prevention interventions may not be
effective. The Cochrane review for instance concluded
that general health checks performed in healthy individ-
uals do not reduce morbidity or mortality, nor in overall
cardiovascular or cancer causes. [32] The Danish Inter99
randomised trial revealed that systematic screening for
risk factors of ischaemic heart disease, followed by indi-
vidually tailored intervention had no effect after 10 years
and did not reduce incidence of stroke, ischaemic heart
disease, as well as mortality rate [44]. On the other hand
Si S. et al. showed that health checks are associated with
statistically significant, though clinically small, improve-
ments in surrogate outcomes, especially in high risk in-
dividuals [33].
Interpretation of results
The readers of our overview should take into consider-
ation that the results concerning the effectiveness of
TRA comes not from primary studies but are strictly
limited to results published in SRs and meta-analyses.
Data derived from these types of studies are the most
useful evidence in clinical practice [6]. However, our
analysis shows a diversity in the quality of included SRs.
The majority of them are, according to AMSTAR, of
medium quality. We also present the quality of evidence
of primary studies as assessed by authors of the included
SRs. Most of them reported a low quality of primary
studies. In accordance with the authors of these SRs, we
agree that conducting further research is still necessary,
in order to obtain more persuasive evidence for TRA
effectiveness in primary prevention.
There are many reasons why TRA may not be effective
and they are described in the literature. Firstly, false
positive results of TRA may cause medical treatment
which is unnecessary and brings risk of side effects. Sec-
ondly, false negative results may cause the lack of appro-
priate treatment [6]. Thirdly, only a small number of
risk variables are included in most of the models (they
do not include e.g. family history, TG level, or obesity).
Risk categories can be arbitrary (e.g. low, medium, high).
In addition, mortality and morbidity rates are declining
in most European countries but prediction models are
based on historic data and may not apply to the popula-
tion to be assessed. Moreover, a small change in one of
the individual risk factors (e.g. blood pressure) from 1
day to another can markedly change patients’ estimated
CVD risk. Finally many physicians identify their patients’
CVD risk factors and launch appropriate treatment
without the necessity of TRA [45].
Implications
Even though TRA is recommended by major clinical
practice guidelines, medical professionals should be
aware that current, limited and of low quality, evidence
from SRs indicate a possible lack of its clinical effective-
ness. Using TRA tools will not harm the patients. There
are no grounds to conclude that, in clinical practice,
CVD risk assessment based on other than TRA
methods, e.g. only on one particular risk factor or count-
ing the number of risk factors instead of using TRA, is
inappropriate. However, there are several other potential
benefits associated with the use of TRA which are con-
sidered in the current guidelines.
Guideline authors should consider re-evaluating the
class of recommendations. In the 2016 European Guide-
lines on CVD prevention [6], the recommendation for
routine use of the SCORE algorithm in primary preven-
tion of CVD is marked as class I. This means that there
is “evidence and/or general agreement that a procedure
is beneficial, useful, effective”. Results of our overview
indicate that in this case, class IIb (“usefulness/efficacy is
less well established by evidence/opinion”) would be
more appropriate. In the British NICE clinical guideline
CG181 [43] (concerning lipid modification for the pri-
mary and secondary prevention of CVD), the strength of
the recommendations in individuals without CVD
should also be lowered from “offer” to “consider”.
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Researchers should plan and perform impact studies
(probably RCTs) which take into account important end-
points e.g. CVD mortality and morbidity, to ultimately
confirm the effectiveness or lack of effectiveness of TRA.
Development of a new model of TRA and looking for
the most appropriate format of its communication also
seems inappropriate when effectiveness is not proven.
Due to the probability of TRA ineffectiveness, the search
for an utterly new method allowing the indication of
points of onset and intensification of intervention in
CVD primary prevention should be started.
Both researchers and guideline authors should be
aware that it is inappropriate to use the models prepared
and validated for prediction purposes to make clinical
decisions concerning patients. It may be especially mis-
leading if thresholds are based on opinions (which are
cheap and quick) and not on impact studies.
Founders and policymakers ought to be aware that
spending resources on adopting TRA into practice may
be against current evidence which is not strong.
In the protocol of our overview, we expressed optimism
that our study might allow patients to have information
about a strong scientific background of performed CVD
risk assessment. We had hoped that this knowledge would
boost patients’ adherence to their physicians’ recommen-
dations. However, these hopes have turned out to have
been in vain.
Conclusion
SRs identified and included in our overview show a lim-
ited evidence, of low overall quality, suggesting a pos-
sible lack of effectiveness of TRA in reducing CVD
events and mortality, as well as a clinically insignificant
influence on individual risk factor levels. These studies
also reveal that using TRA does not cause harm to pa-
tients. Presented results cannot be considered final and
further research is still necessary, however broad imple-
mentation of TRA by practice might be devoid of justifi-
cation based on evidence and should be reconsidered.
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